Welcome to our dedicated page for Bone Biologics news (Ticker: BBLG), a resource for investors and traders seeking the latest updates and insights on Bone Biologics stock.
Bone Biologics Corporation (NASDAQ: BBLG, BBLGW) is a biotechnology company developing orthobiologic products for spine fusion markets, with a focus on bone regeneration using NELL-1-based technology. This news page brings together company announcements and disclosures that highlight its scientific, clinical, operational and capital markets activities.
Readers can review updates on Bone Biologics’ lead product candidate NB1, which the company describes as a combination of recombinant human NELL-1 (rhNELL-1) and demineralized bone matrix for use as a bone graft in spinal fusion procedures. News items include descriptions of the company’s first-in-human clinical study in degenerative disc disease, where NB1 is being evaluated for safety and preliminary effectiveness in transforaminal lumbar interbody fusion.
Coverage also includes operational milestones such as extensions of rhNELL-1 shelf life from earlier 12- and 18-month validations to a reported 24-month validated shelf life, as well as formulation improvements intended to support scaled manufacturing. Intellectual property developments, including the filing of a U.S. patent application for compositions of rhNELL-1 polypeptide and uses in treating bone conditions, are documented in press releases.
Investors and observers can find information on public offerings of common stock and warrants, reverse stock split actions, and communications about Nasdaq listing compliance. The company’s participation in investor conferences and stockholder letters discussing clinical progress, manufacturing readiness, and outlook for NB1 are also reflected in the news flow. This page serves as a centralized source for Bone Biologics’ historical news, helping users follow its orthobiologic development program and related corporate events over time.
Bone Biologics (Nasdaq: BBLG), a developer of orthobiologic products for spine fusion markets, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. Jeffrey Frelick, the company's CEO, will deliver a virtual presentation, which will be accessible online starting September 9th at 7:00 a.m. Eastern time.
The presentation will remain available on the company's website for a time. Bone Biologics' management team will also be available for virtual one-on-one meetings throughout the conference. Institutional investors and industry professionals can choose to attend the conference either virtually or in-person at the Lotte New York Palace Hotel.
Bone Biologics (Nasdaq: BBLG), a developer of orthobiologic products for spine fusion markets, has announced a $2.1 million gross proceeds from the exercise of warrants. The company entered into a definitive agreement for the exercise of existing warrants to purchase 781,251 shares of common stock at $2.43 per share. In exchange, Bone Biologics will issue new unregistered warrants to purchase up to 1,562,502 shares of common stock at $2.00 per share.
The new warrants will have varying terms: half with a five-year term and half with an eighteen-month term. H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close around August 2, 2024. Bone Biologics plans to use the net proceeds to fund clinical trials, maintain and extend its patent portfolio, and for working capital and general corporate purposes.
Bone Biologics (Nasdaq: BBLG) has commenced the first treatments in its pilot clinical study evaluating the NB1 bone graft device for spine fusion in patients with degenerative disc disease (DDD). The study, involving 30 patients, aims to assess the safety, effectiveness, fusion success, pain relief, functional improvement, and adverse events of NB1. The first two patients were treated in Australia. The U.S. FDA has reviewed and agreed upon the study's design, which could support a pivotal U.S. trial. CEO Jeffrey Frelick highlighted NB1's potential to address a $3 billion global spine fusion market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.